We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
-12.77%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$44.2B
AUM Growth
-$8.44B
(-16%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
14.01%
Holding
2,360
New
150
Increased
1,005
Reduced
998
Closed
187
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$209M |
| 2 |
CVS Health
CVS
|
+$195M |
| 3 |
Tyson Foods
TSN
|
+$136M |
| 4 |
ExxonMobil
XOM
|
+$135M |
| 5 |
LyondellBasell Industries
LYB
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$239M |
| 2 |
Microsoft
MSFT
|
+$204M |
| 3 |
Johnson & Johnson
JNJ
|
+$157M |
| 4 |
Amazon
AMZN
|
+$144M |
| 5 |
Walmart Inc
WMT
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.23% |
| 2 | Healthcare | 16.49% |
| 3 | Financials | 11.74% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 10.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
WEC Energy
WEC
$35.1B
| $76.6M | 0.17% |
766,303
+34,678
| +5% | +$3.52M |
|
152
Target
TGT
$68B
| $76M | 0.17% |
552,162
-88,133
| -14% | -$16.9M |
|
153
Jabil
JBL
$35.8B
| $75.2M | 0.17% |
1,488,759
+137,404
| +10% | +$7.96M |
|
154
Landstar System
LSTR
$6.21B
| $75M | 0.17% |
519,624
+5,009
| +1% | +$746K |
|
155
Bank of America
BAC
$442B
| $74.4M | 0.17% |
2,415,796
+1,256,139
| +108% | +$45.2M |
|
156
Old Republic International
ORI
$10.4B
| $74M | 0.17% |
3,311,306
+1,241,181
| +60% | +$28.7M |
|
157
Progressive
PGR
$125B
| $73.9M | 0.17% |
647,975
-39,573
| -6% | -$4.49M |
|
158
CME Group
CME
$94.8B
| $73.9M | 0.17% |
363,662
-19,710
| -5% | -$4.18M |
|
159
Vishay Intertechnology
VSH
$5.43B
| $73.8M | 0.17% |
4,184,675
+1,148,417
| +38% | +$21.8M |
|
160
T-Mobile US
TMUS
$190B
| $72.9M | 0.16% |
545,388
-49,603
| -8% | -$6.47M |
|
161
Phillips 66
PSX
$81.4B
| $72.8M | 0.16% |
888,094
+586,601
| +195% | +$54.3M |
|
162
Schneider National
SNDR
$6.25B
| $72.6M | 0.16% |
3,274,628
+404,251
| +14% | +$9.32M |
|
163
Agilent Technologies
A
$41.2B
| $72M | 0.16% |
614,441
-149,668
| -20% | -$18.4M |
|
|
PPL
164
PPL Corp
PPL
$26.7B
| $71.8M | 0.16% |
2,665,431
+1,998,852
| +300% | +$57.4M |
|
165
Incyte
INCY
$24.4B
| $71.7M | 0.16% |
955,820
+101,765
| +12% | +$7.73M |
|
166
Lincoln National
LNC
$8.81B
| $71.4M | 0.16% |
1,568,919
+1,112,215
| +244% | +$63.4M |
|
167
Organon & Co
OGN
$3.57B
| $71.2M | 0.16% |
2,108,406
-1,013,135
| -32% | -$35.5M |
|
168
Toll Brothers
TOL
$14.5B
| $68.8M | 0.16% |
1,586,659
+432,463
| +37% | +$20.2M |
|
169
Teradata
TDC
$2.55B
| $68.4M | 0.15% |
1,874,849
+552,870
| +42% | +$22.1M |
|
170
Ameren
AEE
$30.1B
| $66.9M | 0.15% |
743,465
-93,364
| -11% | -$8.64M |
|
171
UGI
UGI
$7.33B
| $66.6M | 0.15% |
1,732,362
+115,265
| +7% | +$4.47M |
|
172
Popular Inc
BPOP
$11.1B
| $66.4M | 0.15% |
872,067
-51,525
| -6% | -$4.1M |
|
173
Allison Transmission
ALSN
$9.82B
| $65.3M | 0.15% |
1,726,848
+821,347
| +91% | +$31.4M |
|
174
C.H. Robinson
CHRW
$17.5B
| $64.9M | 0.15% |
642,444
-140,328
| -18% | -$14.7M |
|
175
Starbucks
SBUX
$120B
| $64.5M | 0.15% |
857,833
+273,350
| +47% | +$21M |
|
Similar funds
VGA
AQR Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, AQR Capital Management held 2,360 positions worth $44.2B, down 16% from $52.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
AQR Capital Management's Q2 2022 filing shows 150 new, 1,005 increased, 998 reduced and 187 closed positions. Its largest new stake was Fluor: 339,891 shares worth $7.86M. The largest sale was Thermo Fisher Scientific, an estimated $239M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q2 2022 buy was Fluor: 339,891 shares worth $7.86M.
- AQR Capital Management added most to Gilead Sciences in Q2 2022, an estimated $209M increase.
- AQR Capital Management's biggest Q2 2022 reduction was Thermo Fisher Scientific, cutting an estimated $239M.
- AQR Capital Management fully exited Roku in Q2 2022, selling an estimated $32.5M.
- AQR Capital Management's ten largest holdings make up 14% of its $44.2B portfolio in Q2 2022.
- AQR Capital Management opened 150 new positions and closed 187 in Q2 2022.
- AQR Capital Management's portfolio value fell 16% quarter-over-quarter to $44.2B.
Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.